Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.42 UNCHANGED
Streaming Delayed Price Updated: 12:32 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,314,167
Open 15.50
Bid (Size) 15.41 (400)
Ask (Size) 15.44 (600)
Prev. Close 15.42
Today's Range 15.30 - 15.79
52wk Range 12.55 - 30.98
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Summit Therapeutics Announces Proposed Public Offering of Common Stock
From Summit Therapeutics
Via Business Wire

Performance

YTD
-12.0%
-12.0%
1 Month
+4.4%
+4.4%
3 Month
-17.5%
-17.5%
6 Month
-11.6%
-11.6%
1 Year
-31.8%
-31.8%

More News

Read More
News headline image
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
From Summit Therapeutics
Via Business Wire
Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push ↗
Via Chartmill
News headline image
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
Via The Motley Fool
News headline image
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
From Summit Therapeutics
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
From USA News Group
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Summit Therapeutics Stock Dips After Q1 Financial Report ↗
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
From Summit Therapeutics
Via Business Wire
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
Via The Motley Fool
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics
Via Business Wire
News headline image
Summit (SMMT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
From Summit Therapeutics
Via Business Wire
News headline image
One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 15.42
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 07/06/26 12:32 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.50B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.